Streetbeat News

TCNNF

Trulieve Cannabis Corp

Employees

9,000

Industry

Medicinal and Botanical Manufacturing

Open

7.21

Mkt cap

1.5B

Volume

276K

High

7.85

P/E Ratio

-10.92

52-wk high

14.50

Low

7.21

Div yield

N/A

52-wk low

4.75

Needham analyst Matt McGinley has maintained a Buy rating on Trulieve Cannabis (OTC:TCNNF) and increased the price target from $6.5 to $13.5, indicating a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 10:19 am

Trulieve Cannabis Corp. (OTCQX:TCNNF) reported Q4 revenue of $287 million, surpassing estimates and showing an increase from the previous quarter. Adjusted EPS was $0.12, beating estimates. However, the company reported a higher net loss for the full year, with a net loss of $527 million compared to $246 million in 2022. CEO Kim Rivers highlighted the company's focus on cash generation and investments for future growth. Trulieve ended 2023 with $208 million in cash and operates 193 retail dispensaries in the US.

Portfolio Pulse from Nina Zdinjak

February 29, 2024 | 1:10 pm

Trulieve Cannabis (OTC:TCNNF) reported Q4 earnings, beating estimated earnings by 25.0% with an EPS of $-0.12 versus an estimate of $-0.16. However, revenue was down $15.00 million from the same period last year. In the previous quarter, the company also beat EPS estimates which led to an 8.0% increase in share price the following day.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 11:15 am

Trulieve Cannabis (TCNNF) reported Q4 adjusted EPS of $(0.12), surpassing the $(0.16) estimate, with sales of $287.00M exceeding the $267.95M forecast. This represents a 33.33% improvement in losses per share and a 7.11% sales beat year-over-year, despite a 3.85% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 11:02 am

Cannabis stocks experienced significant movements on February 26, 2024, with notable gainers including Rocky Mountain High, Pharmadrug, and Corbus Pharmaceuticals, among others. Conversely, Elixinol Wellness and Affinor Growers led the losers. The movements reflect the volatile nature of the cannabis market.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 9:30 pm

Following Germany's decision to legalize limited cannabis possession, U.S. and Canadian cannabis stocks like Curaleaf Holdings, Trulieve Cannabis Corp., Green Thumb Industries, Cresco Labs, Tilray, and Aurora Cannabis saw movements in their stock prices. Analysts predict significant growth potential in the German market, comparing it to Florida's medical cannabis market. Companies like Tilray and Aurora Cannabis, already established in Germany, are well-positioned to benefit. Curaleaf's affiliate owns a German importer, and High Tide Inc. expressed enthusiasm about entering the German market.

Portfolio Pulse from Maureen Meehan

February 26, 2024 | 9:13 pm

The article discusses the expectations for EBITDA growth among the largest MSOs in the cannabis industry for Q3:23, Q4:23, and the full year 2024. It highlights that sequential quarter growth was negative for ten out of twelve companies, with an overall projected EBITDA decrease of 5.9% from Q3 to Q4:23. However, year-over-year growth is expected to be stronger among smaller companies. The departure of major companies from several markets is noted, with a focus on concentrating on more profitable markets as a key driver for potential better-than-expected performance in 2024. The expected growth in 2024 EBITDA is 13.4%, driven by modest revenue growth and an increase in EBITDA margins. The article suggests that analysts might be underestimating the potential for 2024 due to continuous downward revisions in 2023.

Portfolio Pulse from Viridian Capital Advisors

February 26, 2024 | 6:41 pm

Germany's legalization of limited cannabis possession and consumption has positively impacted U.S. cannabis stocks, with Curaleaf Holdings seeing a 3.1% rise. The move is seen as a step towards broader European legalization, benefiting companies with a presence in Germany like Curaleaf. Other U.S. cannabis stocks also saw gains, while Canadian companies Tilray and Aurora Cannabis had mixed results. The industry views this as a significant opportunity for growth, especially in medical cannabis.

Portfolio Pulse from Maureen Meehan

February 24, 2024 | 5:26 pm

The cannabis sector experienced significant movement on February 23, 2024, with numerous companies seeing substantial gains in their stock prices, while a few faced declines. Notably, AusCann Group Holdings led the gainers with a 279.88% increase, while GreenGro Technologies experienced the most significant loss, closing down 99%. The movement reflects a bullish sentiment across the cannabis space.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 9:30 pm

The article reports significant movements in marijuana stocks for February 22, 2024, listing both gainers and losers. Notable gainers include GreenGro Technologies with a 9900.00% increase and Cara Therapeutics with an 18.31% rise. Major losers were AusCann Group Holdings, down by 56.84%, and Neptune Wellness Solutions, decreasing by 18.82%. The movements reflect the volatile nature of the marijuana stock market.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 9:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.